ArticleBlood2018
Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
Abstract read
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed.
- Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia.International journal of laboratory hematology · 2026Article
- The Disordered Region of ASXL1 Acts as an Auto-Regulator Through Condensation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.Leukemia · 2026Article
- Unleashed condensation by recurrent mutations of an epigenetic regulator promotes cancer.bioRxiv : the preprint server for biology · 2026Article
- Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4.Nature communications · 2026Article
- The Role and Impact of Non-driver Gene Mutations in Myelofibrosis.Current hematologic malignancy reports · 2026Review
- Oncogenic activation of EVC/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.Leukemia · 2026Article
- The Immunological Consequences of Clonal Hematopoiesis in Heart Failure.Immunological reviews · 2026Review
- Association ofAnnals of laboratory medicine · 2026Article
- Unconventional structure and function of PHD domains from additional sex combs-like proteins.The FEBS journal · 2025Article
- Analysis and Interpretation of Somatic NMD-Escaping Variants in Oncogenes and Dual-Function Genes across Adult and Pediatric Cancer Cohorts.medRxiv : the preprint server for health sciences · 2025Article
- The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia.Leukemia · 2025Review
- Article
- Article
- ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights.International journal of hematology · 2025Review
- Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiation.Blood advances · 2025Article
- A mutant ASXL1-BAP1-EHMT complex contributes to heterochromatin dysfunction in clonal hematopoiesis and chronic monomyelocytic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Cohesin mutations in acute myeloid leukemia.Leukemia · 2024Review
- Clonal hematopoiesis and hematological malignancy.The Journal of clinical investigation · 2024Review
- Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation.Stem cell reviews and reports · 2024Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors.
Hui YangSylvester Comprehensive Cancer Center.
Stefan KurtenbachSylvester Comprehensive Cancer Center.
Ying GuoSylvester Comprehensive Cancer Center.
Ines LohseSylvester Comprehensive Cancer Center.
Michael A DuranteSylvester Comprehensive Cancer Center.
Jianping LiSylvester Comprehensive Cancer Center.
Zhaomin LiSylvester Comprehensive Cancer Center.
Hassan Al-AliSylvester Comprehensive Cancer Center.
Lingxiao LiSylvester Comprehensive Cancer Center.
Zizhen ChenState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital and Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Matthew G FieldSylvester Comprehensive Cancer Center.
Peng ZhangSylvester Comprehensive Cancer Center.ORCID 0000-0002-3394-6922
Shi ChenSylvester Comprehensive Cancer Center.
Shohei YamamotoSylvester Comprehensive Cancer Center.
Zhuo LiSylvester Comprehensive Cancer Center.
Yuan ZhouState Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital and Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Stephen D NimerSylvester Comprehensive Cancer Center.
J William HarbourSylvester Comprehensive Cancer Center.
Claes WahlestedtSylvester Comprehensive Cancer Center.
Mingjiang XuSylvester Comprehensive Cancer Center.
Feng-Chun YangSylvester Comprehensive Cancer Center.
Funding
Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Victor L Perez · 2004 to 2026
$12.2MTargeting p300 and lysine acetylation in AMLR01CA166835 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2012 to 2026
$4.6MRole of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignanciesR01CA172408 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI XU, MINGJIANG, YANG, FENG-CHUN · 2014 to 2024
$3.4MEpigenetic Signaling Pathways Contributing to Alcohol DependenceR01AA023781 · NIAAA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HEILIG, MARKUS ALEXANDER, WAHLESTEDT, CLAES ROBERT · 2015 to 2019
$2.1MRole of TET2 in normal hematopoiesis and pathogenesis of myeloid malignanciesR01HL112294 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI XU, MINGJIANG · 2012 to 2016
$1.9MNo-nonsense approach to treat myeloid malignancies with ASXL1 nonsense mutationsR21CA185751 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI XU, MINGJIANG, YANG, FENG-CHUN · 2014 to 2015
$370kEpigenetic Pharmacotherapy for AddictionR41DA042650 · NIDA · EPIGENETIX, INC. · PI COLLARD, JOSEPH · 2016 to 2016
$189kNCI NIH HHS R01 CA166835NCI NIH HHS R01 CA172408NCI NIH HHS R21 CA185751NEI NIH HHS P30 EY014801NHLBI NIH HHS R01 HL112294NIAAA NIH HHS R01 AA023781NIDA NIH HHS R41 DA042650
Abstract
Additional Sex Combs-Like 1 (
Indexed as
AnimalsBone Marrow CellsBromodomain Containing ProteinsCell DifferentiationCell LineageChromatinGain of Function MutationGene Expression Regulation, LeukemicHematopoietic Stem CellsLeukemia, MyeloidMice, TransgenicNuclear ProteinsPromoter Regions, GeneticProtein BindingProto-Oncogene Proteins c-kitProto-Oncogene Proteins c-vavAsxl1 protein, mouseBrd4 protein, mouseBromodomain Containing ProteinsChromatinNuclear ProteinsProto-Oncogene Proteins c-kitProto-Oncogene Proteins c-vavRepressor ProteinsTranscription FactorsVav1 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.